MX2024004171A - Tratamientos conjuntos que usan inhibidores de la proteina arginina n-metil transferasa 5 (prmt5) para el tratamiento de cancer. - Google Patents

Tratamientos conjuntos que usan inhibidores de la proteina arginina n-metil transferasa 5 (prmt5) para el tratamiento de cancer.

Info

Publication number
MX2024004171A
MX2024004171A MX2024004171A MX2024004171A MX2024004171A MX 2024004171 A MX2024004171 A MX 2024004171A MX 2024004171 A MX2024004171 A MX 2024004171A MX 2024004171 A MX2024004171 A MX 2024004171A MX 2024004171 A MX2024004171 A MX 2024004171A
Authority
MX
Mexico
Prior art keywords
prmt5
inhibitors
cancer
treatment
methyl transferase
Prior art date
Application number
MX2024004171A
Other languages
English (en)
Spanish (es)
Inventor
James Gail Christensen
Lars Daniel Engstrom
Peter Olson
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of MX2024004171A publication Critical patent/MX2024004171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024004171A 2021-10-06 2022-10-06 Tratamientos conjuntos que usan inhibidores de la proteina arginina n-metil transferasa 5 (prmt5) para el tratamiento de cancer. MX2024004171A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163252995P 2021-10-06 2021-10-06
PCT/US2022/045895 WO2023059795A1 (en) 2021-10-06 2022-10-06 Combination therapies using prmt5 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2024004171A true MX2024004171A (es) 2024-04-23

Family

ID=84053165

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004171A MX2024004171A (es) 2021-10-06 2022-10-06 Tratamientos conjuntos que usan inhibidores de la proteina arginina n-metil transferasa 5 (prmt5) para el tratamiento de cancer.

Country Status (10)

Country Link
US (1) US20240398795A1 (https=)
EP (1) EP4412607A1 (https=)
JP (1) JP2024538719A (https=)
KR (1) KR20240095421A (https=)
CN (1) CN118251218A (https=)
AU (1) AU2022360837A1 (https=)
CA (1) CA3233157A1 (https=)
IL (1) IL311663A (https=)
MX (1) MX2024004171A (https=)
WO (1) WO2023059795A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023202626A1 (zh) * 2022-04-22 2023-10-26 北京望实智慧科技有限公司 稠和哒嗪酮化合物作为prmt5抑制剂
CN119301101A (zh) * 2022-07-29 2025-01-10 四川科伦博泰生物医药股份有限公司 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0922332D0 (en) * 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
EP3177288A4 (en) * 2014-08-04 2018-04-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3191592A1 (en) * 2014-09-11 2017-07-19 Novartis AG Inhibition of prmt5 to treat mtap-deficiency-related diseases
TW202122387A (zh) 2019-09-12 2021-06-16 美商米瑞替療法公司 Mta協同性之prmt5抑制劑
AU2020410418A1 (en) * 2019-12-18 2022-06-09 Pfizer Inc. Once daily cancer treatment regimen with a PRMT5 inhibitor
WO2021138578A1 (en) * 2019-12-31 2021-07-08 The Trustees Of Indiana University Repurposing fda-approved drugs as a novel cancer therapeutic avenue through inhibition of prmt5

Also Published As

Publication number Publication date
IL311663A (en) 2024-05-01
JP2024538719A (ja) 2024-10-23
CA3233157A1 (en) 2023-04-13
CN118251218A (zh) 2024-06-25
EP4412607A1 (en) 2024-08-14
WO2023059795A1 (en) 2023-04-13
AU2022360837A1 (en) 2024-04-18
KR20240095421A (ko) 2024-06-25
US20240398795A1 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
MX2023011853A (es) Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento del cáncer.
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
MX2023013912A (es) Metodos para inhibir ras.
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
CO2024009571A2 (es) Inhibidores de parp1
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
AU2018278311A1 (en) IRE1 small molecule inhibitors
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
EA202190581A1 (ru) Антисмысловые олигонуклеотиды, нацеленные на scn2a, для лечения энцефалопатии scn1a
MX2024004171A (es) Tratamientos conjuntos que usan inhibidores de la proteina arginina n-metil transferasa 5 (prmt5) para el tratamiento de cancer.
CO2022000481A2 (es) Inhibidores de enzimas
CY1124688T1 (el) Θεραπεια πρωτεϊνουριας
CL2022000091A1 (es) Métodos para tratar la pancreatitis. (divisional de solicitud n° 202100585)
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
BR112022003768A2 (pt) Compostos inibidores de perk
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
MX2023012744A (es) Inhibidores de pcna e inhibidores de egfr para el tratamiento del cancer.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
BR112020019624A8 (pt) Método para tratar a hipoglicemia pós-prandial